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Abstract
Catechol-O-methyltransferase (COMT) is an enzyme that plays a key role in the modulation of catechol-dependent functions
such as cognition, cardiovascular function, and pain processing. Three common haplotypes of the human COMT gene,
divergent in two synonymous and one nonsynonymous (val
158met) position, designated as low (LPS), average (APS), and
high pain sensitive (HPS), are associated with experimental pain sensitivity and risk of developing chronic musculoskeletal
pain conditions. APS and HPS haplotypes produce significant functional effects, coding for 3- and 20-fold reductions in
COMT enzymatic activity, respectively. In the present study, we investigated whether additional minor single nucleotide
polymorphisms (SNPs), accruing in 1 to 5% of the population, situated in the COMT transcript region contribute to
haplotype-dependent enzymatic activity. Computer analysis of COMT ESTs showed that one synonymous minor SNP
(rs769224) is linked to the APS haplotype and three minor SNPs (two synonymous: rs6267, rs740602 and one
nonsynonymous: rs8192488) are linked to the HPS haplotype. Results from in silico and in vitro experiments revealed that
inclusion of allelic variants of these minor SNPs in APS or HPS haplotypes did not modify COMT function at the level of
mRNA folding, RNA transcription, protein translation, or enzymatic activity. These data suggest that neutral variants are
carried with APS and HPS haplotypes, while the high activity LPS haplotype displays less linked variation. Thus, both minor
synonymous and nonsynonymous SNPs in the coding region are markers of functional APS and HPS haplotypes rather than
independent contributors to COMT activity.
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Introduction
Catechol-O-methyltransferase (COMT) is a ubiquitously ex-
pressed enzyme that maintains basic biologic functions by
inactivating a broad range of catechol substrates, including
catecholamines (epinephrine, norepinephrine, and dopamine)
and catecholestrogens. The human COMT gene is located on
chromosome 22, band q11.2 where it encodes two distinct
proteins, soluble COMT (S-COMT) and membrane-bound
COMT (MB-COMT), through the use of alternative promoters
and translation initiation sites [1,2]. S-COMT is predominately
expressed in peripheral tissues, while MB-COMT is predominatly
expressed in brain. The specific cell and tissue distribution of these
isoforms largely overlaps with that of its catechol substrates.
To date, the role of COMT in catechol metabolism has
prompted over 600 investigations of its variants in the etiology of
numerous disorders. Functional polymorphisms in the COMT
gene are associated with dopamine and norepinephrine-dependent
neuropsychiatric disorders such as schizophrenia [3,4], bipolar
disorder [5], obsessive compulsive disorder [6,7], anxiety disorders
[8–10], attention deficit hyperactivity disorder [11,12], addiction
[13], and anorexia nervosa [14,15] as well as neurodegenerative
disorders such as Parkinson’s disease [16,17]. COMT polymor-
phisms have also been associated with the development of
disorders such as cardiovascular disease [18,19] and estrogen-
induced hormonal cancers [20,21], which are characterized by
increased levels of catecholamines and their reactive products in
peripheral tissues.
More recently, COMT has been implicated in the modulation
of persistent pain. Studies show that reduced COMT activity
results in increased pain sensitivity and proinflammatory cytokine
production in animal models [22,23]. These results are consistent
with clinical studies demonstrating that facial pain patients exhibit
lower COMT activity relative to controls [24]. Furthermore,
functional polymorphisms in the COMT gene resulting in reduced
enzyme activity are associated with fibromyalgia [25,26], tempo-
romandibular disorder (TMD) onset [27], experimental pain
sensitivity [27,28], and altered morphine efficacy in cancer pain
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demonstrate that low activity variants of COMT negatively impact
many aspects of physiology and behavior.
Most of these association studies focused on the common single
nucleotide polymorphism (SNP) rs4680 located at codon 158. The
minor 675A allele produces a valine to methionine substitution,
resulting in a less thermostable COMT enzyme that exhibits a 3-fold
reduction in activity [30]. Until late, the nonsynonymous val
158met
allele has been generally accepted as the main source of individual
variation in COMT activity. However, observed associations
between catechol-related disorders and the met
158 allele are modest
and ofteninconsistent.In the hope of capturing additional functional
COMT polymorphisms that contribute to disease phenotype,
investigators have begun casting larger nets that extend beyond
rs4680. Recent reports have demonstrated associations between the
minor alleles of rs2097603 located in the MB-COMT promoter
region, rs737865 located in intron 1, rs6267 located in exon 3, and
rs165599 located in the 39 untranslated region and enzymeamount/
activity as well as COMT-dependent phenotypes [31–35]. Thus,
emerging evidence suggests that there are multiple functional
interacting SNPs within the COMT gene locus.
Applying this approach to the study of pain disorders, our group
identified three major COMT haplotypes consisting of three SNPs
in the coding region, rs4633 (C/T), rs4818 (C/G), and the
commonly studied rs4680 (G/A), that are strongly associated with
experimental pain sensitivity and likelihood of developing TMD
[27,36]. On the basis of subjects’ pain responsiveness, haplotypes
were designated as low (LPS; CGG), average (APS; TCA), or high
(HPS; CCG) pain sensitive. Individuals carrying APS/APS or
HPS/APS diplotypes were nearly 2.5 times more likely to develop
TMD. In a related study, Vargas-Alarcon and colleagues found
that the HPS haplotype was associated with fibromyalgia risk and
symptom severity [26]. APS and HPS haplotypes associated with
pain sensitivity code for functional changes in COMT. In cells
expressing S- or MB-COMT, the APS haplotype displays a
modest 3-fold reduction in enzymatic activity likely due to the
previously reported decrease in protein thermostability coded by
the met
158 allele. The HPS haplotype, however, exhibits a marked
20-fold reduction in enzymatic activity paralleled by reduced
protein translation efficiency due to formation of a longer more
stable mRNA secondary structure with a 17 kcal/mol reduction in
Gibbs free energy [37]. Thus, combinations of commonly
observed alleles in the coding region of the human COMT gene
can impair the activity of enzyme crucial for a variety of essential
functions such as cognition, cardiovascular tone, and pain
processing.
While LPS, APS, and HPS haplotypes of the COMT gene are
common in the population, accounting for nearly 96% of all
detected haplotypes in the coding region [27], a significant number
of less common minor SNPs are also situated in this region. The
presence of such minor SNPs in the major COMT haplotypes could
be 1) compensatory, rescuing COMT activity by annulling the effects
of their parent haplotypes [38], 2) neutral, carried with common
selectively favored variants [39], or 3) deleterious, further reducing
COMT activity through independent mechanisms or through
interactions with other functional variants [40].
Thus, the purpose of the present study was to identify and
characterize the potential functional effects of additional SNPs
within the COMT gene. An EST database search was first
performed to identify minor SNPs situated in the transcript region
of the COMT gene that were linked with the major haplotypes. We
identified a total of four minor SNPs that were linked to
haplotypes associated with heightened pain sensitivity: rs769224
(800A) was carried with the APS haplotype, while rs6267 (417T),
rs740602 (422A) and rs8192488 (641T) were carried with the HPS
haplotype. Subsequent in vitro and in silico experiments were
performed to assess the functional impact of minor SNPs on
mRNA secondary structure formation, RNA transcription, protein
translation, and enzymatic activity.
Results
EST-based identification of minor SNPs linked to
common haplotypes of the COMT gene
We first investigated the occurrence of SNPs within the COMT
transcript region with lower frequency compared to commonly
observed SNPs constituting the three major haplotypes. To
identify minor COMT SNPs potentially linked to major haplo-
types, we searched the existing NCBI expressed sequence tag
(EST) database. As this database contains over 6 million human
ESTs obtained from many unrelated sources, the variation in
ESTs reflects genotypic variation naturally existing in the
population.
We identified 939 human ESTs that shared greater than 95%
sequence similarity over 100 nucleotides with MB-COMT mRNA.
Of these, 306 ESTs included the positions of all three SNPs in the
coding region (rs4633, rs4818 and rs4680) needed to identify the
major COMT haplotypic structure. Based on their sequence, 138
ESTs were assigned to the LPS haplotype, 109 to the APS
haplotype, and 53 to the HPS haplotype. Six ESTs were not linked
to any of the three major COMT haplotypes and were thus
excluded. Of the remaining 300 ESTs, 19 carried one known SNP
with frequency of at least 1% ([41]; Table 1). Six ESTs carried the
minor 417T allele of SNP rs6267, 4 carried the minor 422A allele
of SNP rs740602, 3 carried the minor 641T allele of SNP
rs8192488, and 6 carried the minor 800A allele of SNP rs769224.
The 800A minor SNP was linked to the APS haplotype, while the
417T, 422A and 641T minor SNPs were linked to the HPS
haplotype.
Compared to SNPs constituting the LPS, APS, and HPS
haplotypes, the above minor SNPs were less frequent in the
population and did not coexist with one another. Therefore, these
minor SNPs likely represent younger mutations that should be
linked to the major haplotypes [42]. Interestingly, there was an
inverse relationship between the frequency of minor SNPs and
major haplotypes in the EST database. Three minor SNPs were
identified in the least frequent HPS haplotype, one minor SNP was
identified in the APS haplotype, and no minor SNPs were
identified in the most frequent LPS haplotype. As LPS is the older
haplotype, showing inter-species conservation at the level of RNA
secondary structure [37], deviation from this haplotype may have
functional implications- negative or positive. The polymorphic
pattern exhibited by the more recent APS and HPS haplotypes
could indicate the evolution of compensatory SNPs that
counteract deleterious effects of low activity haplotypes
[39,43,44]. Alternatively, the presence of additional variation in
the low activity APS and HPS haplotypes could simply be neutral
or nearly neutral. Thus, subsequent studies were conducted to
determine if these minor frequency SNPs naturally occurring
within the APS and HPS haplotypes produce compensatory,
neutral, or negative effects on COMT enzymatic activity at
various levels along the canonical pathway from gene to RNA to
active protein.
Effect of minor SNPs on mRNA secondary structure
associated with common COMT haplotypes
Next, we tested whether minor SNPs linked to haplotypes
associated with heightened pain sensitivity restore function of the
Enrichment of Marker COMT SNPs
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structure which impacts protein translation efficiency [45]. The
800A and 641T minor alleles carried with the APS and HPS
haplotypes, respectively, are situated in a stem-loop structure in
the val
158 region shown to be important for COMT protein
translation [37]. Thus, 800A and 641T minor alleles may modify
this local stem-loop and ultimately affect protein translation. While
the 417T and 422A minor alleles carried with the HPS haplotype
are located further away from the val
158 region in linear space,
they could interact with this region when folded or alter a remote
stem-loop structure also important for protein translation.
To determine whether minor SNPs linked to APS and HPS
haplotypes modify mRNA secondary structure, secondary struc-
tures were predicted for the APS, APS+800A, HPS, HPS+417T,
HPS+422A, and HPS+641T mRNA transcripts using the RNA
Mfold [46] and Afold [47] programs. Several structural domains
were predicted within the 449 nucleotide region that contained the
previously studied val
158 SNP as well as the newly studied minor
SNPs (Fig. 1). In line with previous studies [37], the HPS
haplotype codes for a longer more stable secondary structure in
the val
158 region relative to the APS haplotype. The 800A and
641T minor alleles located within the structural domain of the
val
158 region did not significantly alter this local stem-loop
structure or nearby structural domains associated with the APS
and HPS haplotypes, respectively. The 417T or 422A minor
alleles were located outside of the structural domain of the val
158
region, within separate stem-loop structures. Inclusion of either
417T or 422A minor alleles in the HPS haplotype did not alter
their local stem-loop structure or that of the nearby structural
domain of the val
158 region. These computer modeling results as
well as potential independent effects of minor SNPs carried with
the major haplotypes were studied further in in vitro cell
transfection experiments.
Effect of minor SNPs on COMT RNA abundance, protein
expression, and enzymatic activity
To assess the potential functional impact of minor SNPs at the
level of RNA transcription, PC12 cells were transiently transfected
in duplicate with expression constructs corresponding to the major
LPS, APS, and HPS haplotypes as well as the APS (APS+800A)
and HPS (HPS+417T, HPS+422A, and HPS+641T) haplotypes
containing individual alleles of minor SNPs and then RNA
abundance was measured using real time PCR.
In agreement with results from previous reports [27,37], LPS,
APS, and HPS haplotypes exhibited uniform levels of COMT
RNA abundance (Fig. 2A). Inclusion of the 800A minor allele in
the APS haplotype or the 417T, 422A, or 641T minor alleles in
the HPS haplotype did not alter RNA abundance relative to that
exhibited by the respective parent haplotypes. As previous studies
demonstrated that COMT haplotype-dependent RNA abundance
does not parallel protein expression or enzyme activity [27,37],
minor SNPs may produce effects downstream of RNA transcrip-
tion.
To directly assess the potential functional impact of minor SNPs
at the level of protein translation and activity, PC12 cells were
transiently transfected in duplicate with constructs corresponding
to the three major haplotypes or with the APS or HPS haplotype
constructs containing individual allelic variants of minor SNPs (as
listed above). Protein expression and enzymatic activity were
subsequently measured using Western blot analysis and normeta-
nephrine ELISA, respectively.
Consistent with previous studies [37], protein expression levels
exhibited by the APS haplotype did not differ relative to the LPS
haplotype, while expression levels displayed by the HPS haplotype
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PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5237Figure 1. Effect of minor SNPs linked to APS and HPS haplotypes on predicted mRNA secondary structures. Polymorphic alleles C389T,
C611G, and G675A that define the three major haplotypes are indicated, minor SNPs underlined, and the major functional RNA stem-loop structure
associated with APS and HPS circled. Relative to the APS haplotype, the HPS haplotype coded for a longer, more stable secondary structure.
Transcripts carrying the 800A or 641T mutations in the val
158 region or the 417T or 422A mutations in the nearby stem-loop did not significantly alter
mRNA secondary structure.
doi:10.1371/journal.pone.0005237.g001
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PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5237were reduced 4.5-fold (F6,7=6.13, P,0.02; Fig. 2B and 2C).
Inclusion of the 800A minor allele in the APS haplotype or the
417T, 422A, or 641T minor allele in the HPS haplotype did not
alter protein expression relative to that exhibited by the respective
parent haplotypes.
Also consistent with previous studies [37], enzymatic activity
corresponding to both the APS and HPS haplotypes was reduced
compared to the LPS haplotype (F6,7=9.24, P,0.005; Fig. 2D).
The APS haplotype showed a moderate 3.5-fold reduction, while
the HPS haplotype displayed a marked 58-fold reduction in
enzymatic activity. Again, inclusion of individual minor alleles in
the APS or HPS haplotypes did not produce effects significantly
different from those associated with the parent haplotypes. It is
important to note that the NMN ELISA has adequate sensitivity to
detect reductions in enzymatic activity beyond those associated
with the HPS haplotype. Cells transfected with clones correspond-
ing to the HPS haplotype exhibited 5.6 ng/ml absolute NMN
protein (the enzymatic activity values displayed in Figure 2 are
relative values, as defined by the y-axis label). The kit is sensitive
enough to detect 0.6 ng/ml NMN protein, and thus capable of
capturing a 9.3–fold decrease in enzymatic activity relative to the
HPS haplotype. Taken together, these results suggest that the
synonymous and nonsynonymous minor SNPs tested herein do
not significantly alter functional effects on COMT enzymatic
activity produced by the met
158 allele associated with the APS
haplotype and the mRNA secondary structure associated with the
HPS haplotype and, thus, can be considered neutral.
Discussion
Our results are in line with those from previous studies
demonstrating that the APS and HPS haplotypes, albeit to a
different degree and through different mechanisms, both impair
COMT function. The met
158 allele included in the APS haplotype
codes for a ,3-fold reduction in COMT activity, but not amount,
that is due to reduced stability of the enzyme at normal physiologic
temperature. The HPS haplotype codes for a $20-fold reduction
in COMT activity that is due to the longer more stable local stem-
loop structure in the val
158 region that reduces protein translation
efficiency.
As an extension of this work, we next tested whether additional
SNPs situated in the transcript region that occur at lower
frequency in the population contribute to variation in COMT
activity. We identified a total of four such minor SNPs that were
linked to APS or HPS haplotypes. Interestingly, there was an
inverse relationship between the frequency of minor SNPs and
Figure 2. Effect of minor SNPs linked to the APS and HPS
haplotypes on COMT RNA abundance, protein expression, and
enzymatic activity. (A) The relative abundance of RNA was uniform
among cells transfected with constructs corresponding to the LPS, APS,
and HPS haplotypes. Inclusion of the 800A mutation in the APS
construct or the 417T, 422A, or 641T mutation in the HPS construct did
not alter RNA abundance relative to that exhibited by the respective
parent haplotypes. Data from (B) independent and (C) pooled Western
blot experiments reveal that in cells expressing COMT, the HPS
haplotype exhibited a significant reduction in protein expression
compared to the LPS haplotype. This effect was not altered by
inclusion of the 417T, 422A, or 641T mutations. (D) Both the APS and
HPS haplotypes showed reduced enzymatic activity compared to the
LPS haplotype. The modest reduction in enzymatic activity displayed by
the APS haplotype and the marked reduction displayed by the HPS
haplotype was not altered by inclusion of individual allelic variants of
minor SNPs. Data are Mean6SEM. *P,0.05 and **P,0.01 different from
the LPS haplotype.
doi:10.1371/journal.pone.0005237.g002
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minor SNPs were linked to the least frequent HPS haplotype
coding for the least COMT activity, while one was linked to the
APS haplotype coding for average COMT activity, and none were
linked to the most common LPS haplotype coding for the highest
COMT activity. The distribution of minor SNPs exclusively
within haplotypes coding for reduced COMT activity may suggest
different evolutionary models (e.g., enrichment for functional
compensatory mutations or positive selection leading to carrying of
neutral mutations) depending on the functional contribution of
these SNPs.
Compensatory SNPs have been shown to restore fitness by
suppressing the deleterious effects of nonsynonymous mutations on
receptor folding, DNA-binding, and enzymatic activity
[31,43,48,49]. Thus, minor SNPs linked to the APS haplotype
may compensate for the decreased enzyme thermostability
produced by the met
158 allele. Compensatory SNPs have also
been shown to normalize RNA secondary structure formation
altered by synonymous pathogenic mutations [38,45,50,51]. Thus,
minor SNPs linked to the HPS haplotype may compensate for the
loss of Gibbs free energy in the RNA stem-loop structure. In
contrast to compensatory SNPs, the existence of neutral SNPs in
APS and/or HPS haplotypes would indicate positive selection for
haplotypes associated with reduced COMT activity. As COMT
regulates neuronal and non-neuronal cellular pathways important
for a vast number of basic and complex biologic functions, reduced
COMT leading to elevated catecholamine levels could also be
beneficial.
To test whether minor SNPs linked to APS or HPS haplotypes
rescue COMT activity, further reduce it, or produce neutral
effects, a series of molecular modeling and cell culture studies were
performed. Inclusion of the 800A (rs769224) minor allele in the
APS haplotype or the 417T (rs6267), 422A (740602), or 641T
(rs8192488) minor alleles in the HPS haplotype did not alter
mRNA folding, RNA transcription, protein translation, or
enzymatic activity. The possibility remains that inclusion of minor
SNPs with APS and HPS haplotypes produces very subtle effects
that were not detected using our methods and might still have
effects on individual fitness or that inclusion of minor SNPs
produces functional effects on molecular phenotypes not evaluated
in the present study.
Therefore, these minor SNPs are likely neutral variations versus
functional contributors to COMT activity. However, these data
are inconsistent with a simple model of an ancestral selectively
advantageous haplotype and two derived deleterious haplotypes.
Under a typical population genetic model the ancestral LPS
haplotype should have the highest number of neutral variants,
even if undergoing strong purifying selection for high activity [52].
Likewise, the more recent APS and HPS haplotypes should have a
smaller number of neutral variants if undergoing background
selection for deleterious low activity [52]. Why these haplotypes
are more variable than the LPS haplotype is puzzling. What
evolutionary processes could cause a departure from a simple
model of ancestral selectivity? One possibility is that APS and HPS
haplotypes are not unconditionally deleterious, but under
balancing selection due to pleiotropic effects on traits other than
pain sensitivity. For example, the counterintuitive selection for low
activity COMT haplotypes associated with high pain, anxiety, and
stress response may be driven by a gain of cognitive function
related to higher dopamine and norepinephrine levels. An inverted
U-shaped relationship exists between catecholamine levels and
cortical function, such that intermediate levels are optimal for
cognition [3]. Reduced COMT activity would produce a
rightward shift in the inverted U-shaped curve, leading to higher
levels of catecholamines associated with increased cognitive
function advantageous for memory and attention tasks. Thus,
both high and low activity haplotypes, each with opposing
advantages and disadvantages, may be maintained in the
population due to balancing selection [53]. While there is no
evidence, to date, of greater sequence variation in the COMT
locus than that expected under a neutral model [54], the
distribution of minor SNPs exclusively within haplotypes associ-
ated with reduced COMT activity requires further study. The
balancing selection hypothesis would need to be addressed by 1)
thorough re-sequencing of the COMT gene locus followed by
haplotype-based and linkage-disequilibrium-based analyses
[52,55], 2) thorough phenotyping of individuals for multiple traits
(e.g., pain, cognition, and memory function), and 3) development
of more complex population genetic models to account for
pleiotropic selection. Whether advantageous or disadvantageous
phenotypes associated with low activity COMT haplotypes are
ultimately expressed, is probably determined by additional genetic
and non-genetic factors.Although the significant functional impact
of common APS and HPS haplotypes is independent of minor
SNPs situated in the coding region of the gene, it is possible that
effects of APS and HPS haplotypes are modified by epistatic
interactions occurring at nearby COMT gene loci not investigated
here. A previous report demonstrated that the minor allele of
rs2097603 located in the MB-COMT promoter region associated
with schizophrenia [34] was found to produce a 1.5-fold reduction
in lymphocyte COMT activity independent of the val
158met allele
[56]. Additionally, a haplotype consisting of two noncoding SNPs,
rs737865 in intron 1 and rs165599 in the 39 untranslated region
was associated with Schizophrenia [35] and reduced expression of
COMT mRNA [57]. These SNPs are not in high LD with the
SNPs constituting the three major haplotypes, however may still
interact with the coding SNPs to influence the net size and
direction of effect. Furthermore, a haplotype consisting of the
minor alleles of rs737865 and rs4818 in the HPS haplotype are
associated with increased thermal threshold variance, implicating
a role for additional unobserved functional polymorphisms [40]. It
is also possible that the effects of APS and HPS haplotypes are
modified by epistatic interactions with mutations located in
convergent molecular pathways. For example, hyperhomocystei-
nemia is an important risk factor for a variety of conditions
associated with low COMT activity, including neurodegenerative
disorders, cardiovascular disease, and hormonal cancers [58].
Homocysteine is a precursor for the biosynthesis of S-adenosyl-L-
homocysteine (SAH) which is a strong, noncompetitive inhibitor of
COMT. Functional polymorphisms in genes relevant to homo-
cysteine metabolism (e.g., 5,10-methylenetetrahydrofolate reduc-
tase; MTHFR and glutamate carboxypepidase II; GCPII [59–61])
that result in accumulation of SAH likely augment the effects of
APS and HPS haplotypes. In fact, a recent report demonstrated
that individuals homozygous for low enzyme activity alleles of the
COMT and MTHFR genes in combination, but not alone, are at
increased risk for schizophrenia [62]. Thus, it is possible that
minor SNPs situated within APS and HPS haplotypes compensate
for low COMT activity not at the level we define, but instead
through interactions with other genes or genotypes.
Additionally, the effects of APS and HPS haplotypes may be
modified by nongenetic factors, such as environmental events that
lead to a sustained elevation in catecholamines (e.g., physical and
emotional stress, inflammation, and injury [63–65]) and nutri-
tional deficiencies that contribute to hyperhomocysteinemia (e.g.,
reduced dietary folate, vitamin B12, or vitamin B6 [66,67]). An
example of COMT gene-environment interaction was recently
illustrated by Slade and colleagues, who found that among
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23% for those with a history of orthodontic treatment and 0% for
those with no history of orthodontic treatment [68]. In order to
truly understand the dynamic etiology of complex catechol-
dependent phenotypes, flashlights used to examine the relationship
between one SNP and one phenotype need to be traded in for
floodlights that will illuminate dynamic relationships between
genetic and epigenetic factors. Thus, future studies necessitate
careful consideration as to how polymorphisms within and
between distinct genetic loci interact with one another as well as
with nongenetic factors to place individuals at risk.
The 417T allele was previously associated with clinical effects.
This minor SNP, producing an alanine to serine substitution at
codon 72, has been associated with aggressive behavior and
schizophrenia risk as well as with COMT activity in red blood cells
collected from study participants [32,33]. However, we found that
the functional impact of common APS and HPS haplotypes is
independent of this less frequent second-site mutation situated in
the coding region of the human COMT gene. In light of this, we
can revisit the conclusion regarding effects previously associated
with 417T. In that study, individuals homozygous for 417G (ala
72)
had the highest activity, while those homozygous for 417T (ser
72)
had the lowest activity. Individuals exhibiting both the highest and
lowest COMT activity were homozygous for the val
158 allele,
which is present in both the LPS and HPS haplotypes. In
correspondence with the APS haplotype, individuals exhibiting
average COMT activity were homozygous for the met
158 allele. As
417T is carried exclusively with the HPS haplotype and its
inclusion in this parent haplotype does not alter enzymatic activity,
we can conclude that 417T is a marker of HPS haplotype and that
the low activity associated with the nonsynonymous ser
72 allele is in
fact due to alterations in RNA secondary structure and protein
translation efficiency coded for by the parent HPS haplotype.
In summary, we demonstrated that the impact of common
COMT haplotypes on enzymatic activity is independent of
additional minor SNPs in the coding region of the human COMT
gene. Tight linkage of these neutral polymorphisms with more
recently acquired low activity APS and HPS haplotypes does not
satisfy a simple ancestral model and requires the development of a
more complex population genetic model to account for pleiotropic
selection. The counterintuitive selection for low activity COMT
haplotypes may be driven by a gain of cognitive function, for
example, related to increased catecholamine levels. Thus, the
expression ‘‘no pain – no gain’’ may have literal meaning when
applied to evolution of the human COMT locus.
Materials and Methods
EST database analysis
Using an approach similar to that used previously [69], we first
performed a BLAST search of the human EST database (dbEST
release May 09, 2008) to identify all allelic combinations occurring
within the complete nucleotide sequence of MB-COMT mRNA
(NM_000754.2, length=1289 nucleotides). We then selected all
matching ESTs longer than 100 nucleotides, so that at least 80%
of their length overlapped with the COMT sequence with 95%
similarity. The list of ESTs was then constrained to those
containing all three SNPs in the coding region (rs4633, rs4818
and rs4680) needed to identify the three major COMT haplotypes.
Analysis of nucleotide variation within the three haplotypes was
restricted to SNPs with frequency of at least 1%. The minor allele
frequency of minor SNPs in our constrained EST list correspond-
ed to that annotated in the NCBI dbSNP.
Prediction of RNA secondary structure
Secondary structures of the full-length APS, APS+800A, HPS,
HPS+417T, HPS+422A, and HPS+641T mRNA transcripts were
predicted using the RNA Mfold program (versions 3.1 and 3.2)
[46] and the Afold program [47]. Energy minimization was
performed by a dynamic programming method that finds the
secondary structure with the minimum free energy with sums
comprised of stacking, loop length, etc. [47,70]. The RNA folding
parameters were developed and published by the Turner group
[71]. Suboptimal stem-loop structures were analyzed by the
Hybrid program [72,73] for the full-length COMT transcripts, and
for truncated transcript sequences of different lengths ranging
from the rs4633 to the rs769224 region with 449 nucleotide
window length.
Construction of COMT variants
Previously constructed full-length cDNA COMT clones that
differed only in three nucleotides corresponding to the LPS, APS,
and HPS haplotypes were used [37]. Four individual minor SNPs
were introduced in the parent APS (rs769224; 800GRA) or HPS
(rs6267; 417GRT, rs740602; 422GRA, or rs8192488; 641CRT)
constructs by site directed mutagenesis using the Quickchange II
XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA). Plasmid DNA was purified using the EndoFree Plasmid
Maxi purification kit (Qiagen, Germantown, MD, USA). Once
plasmids were isolated, DNA sequences were confirmed by double
sequencing at the UNC core sequencing facility.
Transient transfection of COMT cDNA clones
A rat adrenal cell line (PC-12) was transiently transfected in six-
well plates using FuGENE 6 Transfection Reagent (Roche, Basel,
Switzerland) in accordance with manufacture’s recommendations.
The amount of plasmid was kept at 1 mg/well. Cells were
cotransfected with pSV-bGalactosidase (0.1 mg/well) and SEAP
(0.1 mg/well) plasmids to control for transfection efficiency and
RNA abundance, respectively (Promega, Madison, WI, USA).
Transfections with the vector lacking the insert were also done for
each experiment. The same cell line was used for analysis of total
RNA, protein expression, and enzymatic activity. Transfection
experiments for analysis of total RNA and protein expression/
enzymatic activity were performed in duplicate concurrently.
Cell lysate was then collected approximately 48 hours post-
transfection.
Real-time PCR
Total RNA was isolated using the Trizol reagent (Invitrogen,
Carlsbad, CA, USA). The isolated RNA was treated with RNase
free-DNase I (Promega) and reverse transcribed by Superscript III
reverse transcriptase (Invitrogen). The cDNA for COMT and
SEAP was amplified with SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) using forward and reverse PCR
primers (TGAACGTGGGCGACAAGAAAGGCAAGAT and
TGACCTTGTCCTTCACGCCAGCGAAAT, respectively, for
COMT and GCCGACCACTCCCACGTCTT and CCCG-
CTCTCGCTCTCGGTAA, respectively, for SEAP). SEAP was
used to normalize COMT RNA abundance for transfection
efficiency. The MCEP Realplex 2S System (Eppendorf, Westbury,
NY, USA) was used for measuring fluorescence.
Western blot
Purified lysates, normalized for protein content using a BCA
assay, were run on 12% Novex Tris-Glycine gels (Invitrogen) and
transferred to nitrocellulose membranes (Whatman, Florham
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with 5% nonfat milk for 30 min at room temperature, incubated
with COMT polyclonal primary antibody (1:10,000; Chemicon,
Temecula, CA, USA) overnight at 4uC, and then incubated with
Goat Anti-Rabbit IgG HRP polyclonal secondary antibody
(1:10,000; Chemicon) for 1 hr at room temperature. Blots were
washed with PBST for 10 min at RT, exposed to chemilumines-
cence reagent (Pierce, Milwaukee, WI, USA), and developed. Blots
were then stripped using Restore western stripping buffer (Pierce)
and equal loading of samples verified by b-actin staining. Blots
were incubated with b-actin polyclonal primary antibody
(1:10,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
1 hr at RT followed by Goat Anti-Rabbit IgG HRP polyclonal
secondary antibody (1:10,000; Chemicon) for 1 hr at RT and
chemiluminescent reagent.
Enzymatic assay
After removal of the media, the cells were washed twice with
0.9% saline (1 ml/well) and covered with deionized water
containing 10 mM CDTA (300 ml/well). The cells were freeze/
thawed (280uC/room temperature) five times and the lysate
collected in 1.7 ml tubes. The tubes were centrifuged at 2,000 g
for 20 minutes and the filtrate removed. The enzymatic COMT
assay procedure followed the protocol described by Masuda’s
group [74]. Purified lysates (8 ml) were incubated with 200 mM
Sadenosyl-L-methionine (SAMe; ICN Chemicals, Aurora OH,
USA), 7.5 mM L-norepinephrine (NE; Sigma Chemical Co., St.
Louis MO, USA) and 2 mM MgCl2 in 50 mM phosphate
buffered saline for 60 min in the final volume of 22 ml. The
reaction was terminated using 20 ml of 0.4 M hydrocholoric acid
and 1 ml of 330 mM EDTA. The same reaction in the presence of
15 mM EDTA was carried out in parallel for each lysate to bind
Mg
+2 ions required for COMT activity. COMT activity was
assessed as measurement of normetanephrine (NMN) by Nor-
metanephrine ELISA kit (IBL, Hamburg, Germany) in accor-
dance with manufacture’s recommendations using 10 ml of above
reaction mixture. COMT activity was determined after subtract-
ing the amount of NMN produced by endogenous enzymatic
activity (transfection with empty vector). The non-specific
background was determined in parallel assays performed in the
presence of EDTA and then subtracted from each reading.
COMT activity was then normalized for transfection efficiency by
measuring the b-galactosidase activity for each lysate. b-galacto-
sidase activity was determined using b-galactosidase enzyme
systems (Promega) in accordance with manufacture’s recommen-
dations. The standard curve for ELISA was determined using a 4
parameter sigmoidal dose-response model for one-site competitive
binding systems. The lowest detectable level that can be
distinguished from the zero standard is 0.6 ng/ml.
Statistical analysis
COMT RNA abundance, protein expression, and enzyme
activity levels from duplicate experiments were analyzed by one-
way analysis of variance (ANOVA). Post hoc comparisons were
performed using Bonferroni’s Multiple Comparison Test. P,0.05
was considered significant.
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